

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Reasons for Delay	Comments	Reasons for delay correspond to:
166032	18/LO/1258	248312	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis - BIOGEN	Yes	21/06/2019	0	59	59	03/07/2018	23/04/2019	18/09/2018	10/04/2019	23/04/2019	14/05/2019			Please Select...
166033	18/EM/0229	250101	A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PARALLEL-GROUP, ACTIVE-CONTROL STUDY OF THE EFFICACY AND SAFETY OF SPARSENTAN FOR THE TREATMENT OF IMMUNOGLOBULIN A NEPHROPATHY - PROTECT	No		14			06/03/2019	30/04/2019	04/10/2018	01/05/2019	14/05/2019		D - Sponsor Delays	Trust still awaiting green light from Sponsor	Sponsor
166034	17/NE/0027	215796	CReST 2 - Colorectal Endoscopic Stenting Trial 2	No		0			23/10/2018	06/06/2019	03/04/2017	03/05/2019	06/06/2019		D - Sponsor Delays	Trust still awaiting Sponsor Green Light	Sponsor
166035	19/NW/0363	250571	Protocol I4V-MC-JAJA (RA-BRIDGE) Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis	No		0			29/05/2019	20/08/2019	08/08/2019	16/08/2019	20/08/2019	27/08/2019	F - No patients seen		Neither
166036	19/SC/0309	264959	A multicenter, open-label extension study to evaluate the long-term safety, tolerability and efficacy of orally administered GLPG1690 in subjects with systemic sclerosis	Yes	10/10/2019	84	27	111	21/06/2019	21/06/2019	20/08/2019	12/09/2019	13/09/2019	30/09/2019	J - Other	This is an extension study, and patients are not eligible for entry until October 2019	Neither
166037	16/ES/0110	207747	Treatment of Osteogenesis Imperfecta with Parathyroid hormone and Zoledronic acid	No		165			04/04/2019	04/04/2019	12/01/2017	04/09/2019	16/09/2019		D - Sponsor Delays	Trust still awaiting green light from Sponsor	Sponsor
166038	19/NW/0342	264974	A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation	Yes	15/01/2020	6	91	97	21/06/2019	10/10/2019	25/07/2019	11/10/2019	16/10/2019	16/10/2019			Please Select...

166039	19/NW/0317	262846	A Phase 2, Double-blind, Randomized, Placebo-controlled, Two-Treatment, Two-Period Crossover Efficacy and Safety Study in Idiopathic Pulmonary Fibrosis with Nalbuphine ER Tablets for the Treatment of Cough	No		21				17/09/2019	16/10/2019	12/07/2019	03/10/2019	06/11/2019	06/11/2019	F - No patients seen	No patients eligible over 200 patients screened	Neither
166040	19/SC/0352	255747	A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis	Yes	17/01/2020	12	38	50		12/07/2019	28/11/2019	02/10/2019	28/11/2019	10/12/2019	10/12/2019			Please Select...
166041	18/LO/1737	240606	Pentoxifylline and Tocopherol for the Treatment of Post-radiotherapy Fibrosis in Head and Neck Cancer Patients: a Feasibility Study	No		186				02/05/2019	02/05/2019	01/11/2018	09/09/2019	04/11/2019		D - Sponsor Delays	Awaiting Green Light following further substantial amendment	Sponsor
166042	19/YH/0222	252494	Positional Therapy for Obstructive Sleep Apnoea: a Randomised Controlled Trial to assess the effect on Health and Wellbeing in Older and Younger People.	No		154				14/06/2019	19/06/2019	24/07/2019	13/11/2019	20/11/2019	21/11/2019	J - Other	Patients identified but did not consent	Neither
166043	18/SC/0666	248460	A multicentre randomised controlled trial assessing the mortality, quality of life, and cost effectiveness of operative rib fixation plus supportive management versus supportive management alone for patients with multiple rib fractures requiring ventilator support.	Yes	20/01/2020	15	34	49		17/09/2019	02/12/2019	09/07/2019	28/11/2019	17/12/2019	17/12/2019			Please Select...
166044	18/SC/0243	240684	HPS-4/TIMI 65/ORION-4: A double-blind randomized placebo-controlled trial assessing the effects of inclisiran on clinical outcomes among people with atherosclerotic cardiovascular disease	Yes	11/03/2020	6	36	42		02/07/2019	29/01/2020	17/10/2018	16/01/2020	04/02/2020	12/02/2020			Please Select...
166045	19/SC/0422	268966	An Open-Label, Long-Term Safety Evaluation of Diazoxide Choline Controlled-Release Tablet in Patients with Prader-Willi Syndrome	Yes	20/02/2020	195	10	205		30/07/2019	30/07/2019	30/09/2019	22/01/2020	10/02/2020	18/02/2020	J - Other	This is a study extension so will not be activated at Aintree until January 2020	Neither
166046	19/NW/0707	272541	A Randomised, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the	Yes	19/02/2020	1	6	7		29/11/2019	12/02/2020	23/01/2020	13/02/2020	13/02/2020	14/02/2020			Please Select...

			Efficacy and Safety of Tirzepatide versus Placebo in Patients with Nonalcoholic Steatohepatitis (NASH).														
166047	19/EM/0188	261137	A Phase 3b Study to Evaluate the Duration of Effect of Bimatoprost SR in Participants with Open-Angle Glaucoma or Ocular Hypertension	No		7			30/09/2019	10/02/2020	12/09/2020	17/02/2020	17/02/2020	30/06/2020	J - Other	Study halted due to COVID 19.	Neither
166050	19/SC/0347	263849	A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 µg of OPN-375 Twice a Day (BID) in Subjects with Chronic Sinusitis With or Without the Presence of Nasal Polyps	No		7			30/07/2019	10/02/2020	15/11/2020	17/02/2020	17/02/2020		J - Other	Screening on hold due to COVID-19	Neither
166052	20/EE/0101	281712	Randomised Evaluation of COVID-19 Therapy (RECOVERY)	Yes	08/04/2020	2	12	14	17/03/2020	25/03/2020	17/03/2020	13/03/2020	27/03/2020	30/03/2020			Please Select...